Insights

Expanding Manufacturing Capacity Delpharm is investing heavily in expanding its production infrastructure, including a recent $140M upgrade at its Canadian facility and a €28M sterile line addition in France. This presents opportunities to offer specialized manufacturing solutions, equipment, and scalable supply chain services.

Strong Focus on Innovation With full development services covering various pharmaceutical forms and collaborations on COVID-19 vaccine production, Delpharm is positioned to require advanced biomanufacturing technologies, high-quality equipment, and innovation-driven contract manufacturing partnerships.

Global Footprint and Market Reach Operating across France, Italy, Canada, the Netherlands, and Poland, Delpharm's international presence offers chances to provide logistics solutions, regional regulatory expertise, and customized supply chain strategies to support their diverse markets.

Strategic Partnerships Recent collaborations with Pfizer, BioNTech, and Sandoz highlight Delpharm's role as a key CDMO partner. This creates openings for strategic service integrations, complementary manufacturing technologies, and joint innovation initiatives.

Customer-Centric Development Delpharm's focus on full development services from clinical batches to commercial production indicates a need for integrated project management, quality assurance tools, and advanced manufacturing software solutions to streamline development workflows.

Delpharm Tech Stack

Delpharm uses 8 technology products and services including ICS Flow, AutoCAD, RSS, and more. Explore Delpharm's tech stack below.

  • ICS Flow
    Business Process Management
  • AutoCAD
    Cad & Graphics
  • RSS
    Content Management System
  • SQL
    Database
  • Ennov
    Enterprise Content Management
  • Chart.js
    Javascript Graphics
  • reCAPTCHA
    Security
  • X-XSS-Protection
    Security

Media & News

Delpharm's Email Address Formats

Delpharm uses at least 1 format(s):
Delpharm Email FormatsExamplePercentage
First.Last@delpharm.comJohn.Doe@delpharm.com
93%
FLast@delpharm.comJDoe@delpharm.com
3%
Last.First@delpharm.comDoe.John@delpharm.com
3%
First.MiddleLast@delpharm.comJohn.MichaelDoe@delpharm.com
1%

Frequently Asked Questions

Where is Delpharm's headquarters located?

Minus sign iconPlus sign icon
Delpharm's main headquarters is located at 9 Face au Boulogne-billancourt, Île-de-france 92100 France. The company has employees across 4 continents, including EuropeNorth AmericaAsia.

What is Delpharm's phone number?

Minus sign iconPlus sign icon
You can contact Delpharm's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Delpharm's official website and social media links?

Minus sign iconPlus sign icon
Delpharm's official website is delpharm.com and has social profiles on LinkedInCrunchbase.

How much revenue does Delpharm generate?

Minus sign iconPlus sign icon
As of February 2026, Delpharm's annual revenue is estimated to be $5B.

What is Delpharm's SIC code NAICS code?

Minus sign iconPlus sign icon
Delpharm's SIC code is 9999 - Nonclassifiable Establishments NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Delpharm have currently?

Minus sign iconPlus sign icon
As of February 2026, Delpharm has approximately 3.9K employees across 4 continents, including EuropeNorth AmericaAsia. Key team members include Chief Executive Officer: N. R.Chief Commercial Officer: S. L.Chief Scientific Officer Delpharm: J. D.. Explore Delpharm's employee directory with LeadIQ.

What industry does Delpharm belong to?

Minus sign iconPlus sign icon
Delpharm operates in the Pharmaceutical Manufacturing industry.

What technology does Delpharm use?

Minus sign iconPlus sign icon
Delpharm's tech stack includes ICS FlowAutoCADRSSSQLEnnovChart.jsreCAPTCHAX-XSS-Protection.

What is Delpharm's email format?

Minus sign iconPlus sign icon
Delpharm's email format typically follows the pattern of First.Last@delpharm.com. Find more Delpharm email formats with LeadIQ.

Delpharm

Pharmaceutical ManufacturingÎle-de-france, France1001-5000 Employees

Delpharm is a worldwide leader in contract manufacturing and development of medicines with : 
- 19 plants in France, Italy, Canada, Poland and The Netherlands
- Over 1,1 billion euros turnover
- Over 6,500 people
- 6,500 people working in the company
- Most dosage forms produced

For over 35 years, Delpharm has grown by progressively acquiring production plants, notably from major pharmaceutical laboratories. Today, Delpharm operates 18 industrial sites and 3 development centers located in France, Italy, Canada, the Netherlands, and Poland, producing over one billion boxes of medicines per year and contributing to the development of numerous projects.

As multi-specialists, Delpharm is able to supply the majority of pharmaceutical forms available on the market, such as tablets and capsules, bottles and injectable ampoules, prefilled syringes, freeze-drying, suspensions, solutions, ointments and soft gel capsules.

Delpharm also offers full development services for a wide range of pharmaceutical forms, chemical entities and innovative combinations, including the production of phase 1 to 3 clinical batches for solid, semi-solid, liquid and injectable forms.

Section iconCompany Overview

Headquarters
9 Face au Boulogne-billancourt, Île-de-france 92100 France
Phone number
SIC Code
9999 - Nonclassifiable Establishments
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Employees
1001-5000

Section iconFunding & Financials

  • $50M$100M

    Delpharm's revenue is estimated to be in the range of $50M$100M

Section iconFunding & Financials

  • $50M$100M

    Delpharm's revenue is estimated to be in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.